# TATE and KN046 in MCRC

> **NCT06834399** · PHASE2 · TERMINATED · sponsor: **Zhejiang Raygene Pharmaceuticals Co., Ltd** · enrollment: 42 (actual)

## Conditions studied

- Colorectal Cancer with Hepatic Metastases

## Interventions

- **DRUG:** KN046 （PD-L1/CTLA4 BsAb）
- **PROCEDURE:** TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization

## Key facts

- **NCT ID:** NCT06834399
- **Lead sponsor:** Zhejiang Raygene Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-27
- **Primary completion:** 2024-12-17
- **Final completion:** 2025-01-09
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Business Operation Strategy Adjustment
- **Last updated:** 2025-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06834399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06834399, "TATE and KN046 in MCRC". Retrieved via AI Analytics 2026-09-10 from https://api.ai-analytics.org/clinical/NCT06834399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*